Biosimilar to Target Autoimmune Conditions in LATAM
Polpharma Biologics has signed a landmark licensing agreement with Tuteur to commercialize a biosimilar for autoimmune diseases across Latin America, excluding Brazil. The deal was announced on 22nd May 2026.
Under the terms of the agreement, Polpharma Biologics will manage the development and manufacturing of the biosimilar. Meanwhile, Tuteur will oversee its commercialization, marketing, and distribution in the licensed territories, aiming to enhance patient access to affordable biological therapies.
Anjan Selz, CEO of Polpharma Biologics, expressed, "Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally. With their strong regional expertise and commercial capabilities in LATAM, we are well-positioned to bring this important therapy to patients living with autoimmune diseases."
Development and Commercialization Plans
The biosimilar is currently in development. It is designed to offer an effective treatment option for patients with autoimmune conditions, and regulatory submission is expected within the next three years to provide a well-tolerated alternative in the market.
Jonathan Hahn, President of Tuteur, noted, "Our collaboration with Polpharma Biologics marks a significant milestone for Tuteur. Partnering with an organisation of their caliber reinforces our commitment to expanding access to world-class biologics for patients throughout Latin America."
Polpharma Biologics, a leading biopharmaceutical company, specialises in the development and manufacturing of biosimilars for global markets. The Switzerland-based biosimilars platform manages the entire value chain, ensuring efficient progression from concept to launch in collaboration with global partners.
The company’s biosimilar portfolio includes multiple programmes at various development stages, from early-stage research to commercialization. Polpharma Biologics is committed to accelerating access to biologic therapies through a robust and expanding pipeline of biosimilars.
Both companies are focused on ensuring that the biosimilar can be effectively distributed and made accessible to patients across the region, with a shared commitment to improving healthcare outcomes. Through partnerships with trusted CDMOs, Polpharma Biologics delivers end-to-end solutions, from cell line development to finished products, in key therapeutic areas.
